A Role for Estrogen Receptor Phosphorylation in the Resistance to Tamoxifen

Overview

Journal Int J Breast Cancer

Publisher Wiley

Date 2012 Feb 2

PMID 22295213

Citations 53

Authors

Renee de Leeuw

Jacques Neefjes

Rob Michalides

Affiliations

Soon will be listed here.

Abstract

About two thirds of all human breast cancer cases are estrogen receptor positive. The drug of first choice for these patients is tamoxifen. However, about half of the recurrences after removal of the primary tumor are or become resistant to this drug. While many mechanisms have been identified for tamoxifen resistance in the lab, at present only a few have been translated to the clinic. This paper highlights the role in tamoxifen resistance of phosphorylation by different kinases on different sites of the estrogen receptor. We will discuss the molecular pathways and kinases that are involved in phosphorylation of ERα and how these affect tamoxifen resistance. Finally, we will elaborate on the clinical translation of these observations and the possibility to predict tamoxifen responses in patient tumor samples before treatment onset. The findings made originally on the bench may translate into a better and personalized treatment of breast cancer patients using an old and safe anticancer drug: tamoxifen.

Citing Articles

Roles of Post-Translational Modifications of Transcription Factors Involved in Breast Cancer Hypoxia.

Seymour L, Nuru N, Johnson K, Gutierrez J, Njoku V, Darie C Molecules. 2025; 30(3).

PMID: 39942749 PMC: 11820228. DOI: 10.3390/molecules30030645.

CDK7 in breast cancer: mechanisms of action and therapeutic potential.

Gong Y, Li H Cell Commun Signal. 2024; 22(1):226.

PMID: 38605321 PMC: 11010440. DOI: 10.1186/s12964-024-01577-y.

Extracellular nicotinamide phosphoribosyltransferase: role in disease pathophysiology and as a biomarker.

Semerena E, Nencioni A, Masternak K Front Immunol. 2023; 14:1268756.

PMID: 37915565 PMC: 10616597. DOI: 10.3389/fimmu.2023.1268756.

Ceramide synthase 4 overexpression exerts oncogenic properties in breast cancer.

Kim S, Seo I, Kim M, Park J, Kim S, Park W Lipids Health Dis. 2023; 22(1):183.

PMID: 37885013 PMC: 10605224. DOI: 10.1186/s12944-023-01930-z.

The impact of poor metabolic health on aggressive breast cancer: adipose tissue and tumor metabolism.

Sankofi B, Valencia-Rincon E, Sekhri M, Ponton-Almodovar A, Bernard J, Wellberg E Front Endocrinol (Lausanne). 2023; 14:1217875.

PMID: 37800138 PMC: 10548218. DOI: 10.3389/fendo.2023.1217875.

References

Massarweh S, Osborne C, Creighton C, Qin L, Tsimelzon A, Huang S . Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008; 68(3):826-33. DOI: 10.1158/0008-5472.CAN-07-2707. View

Cui Y, Zhang M, Pestell R, Curran E, Welshons W, Fuqua S . Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. Cancer Res. 2004; 64(24):9199-208. DOI: 10.1158/0008-5472.CAN-04-2126. View

Chen D, Washbrook E, Sarwar N, Bates G, Pace P, Thirunuvakkarasu V . Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene. 2002; 21(32):4921-31. DOI: 10.1038/sj.onc.1205420. View

Vendrell J, Bieche I, Desmetz C, Badia E, Tozlu S, Nguyen C . Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines. Endocr Relat Cancer. 2005; 12(1):75-92. DOI: 10.1677/erc.1.00899. View

Duplessis T, Williams C, Hill S, Rowan B . Phosphorylation of Estrogen Receptor α at serine 118 directs recruitment of promoter complexes and gene-specific transcription. Endocrinology. 2011; 152(6):2517-26. PMC: 3100622. DOI: 10.1210/en.2010-1281. View

Wu R, Qin J, Yi P, Wong J, Tsai S, Tsai M . Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell. 2004; 15(6):937-49. DOI: 10.1016/j.molcel.2004.08.019. View

Ali S, Coombes R . Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2003; 2(2):101-12. DOI: 10.1038/nrc721. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H . Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995; 270(5241):1491-4. DOI: 10.1126/science.270.5241.1491. View

10.

Jansen M, Ruigrok-Ritstier K, Dorssers L, van Staveren I, Look M, Meijer-Van Gelder M . Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer. Breast Cancer Res Treat. 2008; 116(2):263-71. DOI: 10.1007/s10549-008-0125-z. View

11.

Musgrove E, Sutherland R . Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009; 9(9):631-43. DOI: 10.1038/nrc2713. View

12.

Long W, Yi P, Amazit L, Lamarca H, Ashcroft F, Kumar R . SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. Mol Cell. 2010; 37(3):321-32. PMC: 2824333. DOI: 10.1016/j.molcel.2010.01.004. View

13.

Gustafsson J . An update on estrogen receptors. Semin Perinatol. 2000; 24(1):66-9. DOI: 10.1016/s0146-0005(00)80059-2. View

14.

Michalides R, van Tinteren H, Balkenende A, Vermorken J, Benraadt J, Huldij J . Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer. 2002; 86(3):402-8. PMC: 2375223. DOI: 10.1038/sj.bjc.6600072. View

15.

Barone I, Brusco L, Fuqua S . Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res. 2010; 16(10):2702-8. PMC: 4477803. DOI: 10.1158/1078-0432.CCR-09-1753. View

16.

Skliris G, Rowan B, Al-Dhaheri M, Williams C, Troup S, Begic S . Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomas. Breast Cancer Res Treat. 2008; 118(3):443-53. PMC: 3448371. DOI: 10.1007/s10549-008-0267-z. View

17.

Skliris G, Nugent Z, Rowan B, Penner C, Watson P, Murphy L . A phosphorylation code for oestrogen receptor-alpha predicts clinical outcome to endocrine therapy in breast cancer. Endocr Relat Cancer. 2010; 17(3):589-97. DOI: 10.1677/ERC-10-0030. View

18.

Nagy L, Schwabe J . Mechanism of the nuclear receptor molecular switch. Trends Biochem Sci. 2004; 29(6):317-24. DOI: 10.1016/j.tibs.2004.04.006. View

19.

Zwart W, Griekspoor A, Rondaij M, Verwoerd D, Neefjes J, Michalides R . Classification of anti-estrogens according to intramolecular FRET effects on phospho-mutants of estrogen receptor alpha. Mol Cancer Ther. 2007; 6(5):1526-33. DOI: 10.1158/1535-7163.MCT-06-0750. View

20.

Jansen M, Sieuwerts A, Look M, Ritstier K, Meijer-Van Gelder M, van Staveren I . HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol. 2007; 25(6):662-8. DOI: 10.1200/JCO.2006.07.3676. View